Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR Fellowship

Université de Montréal

$135,000.00

The impact of mTOR and p53 signaling pathways on the MHCI immunopeptidome of cancer cells

EF 2008-09

Résumé
Cancer cells can be killed effectively by T lymphocytes. In accordance with this concept, studies in mice and humans have clearly shown that T lymphocytes can cure cancer. In order to do so however, T lymphocytes must recognize abnormalities on the surface of cancer cells that are not usually present on normal cells. In essence, T lymphocytes recognize a specific group of small molecules (peptides) that are bound to cell surface proteins called MHCI. Collectively, these peptides are referred to as the MHCI immunopeptidome. We know so far that translation of T-cell therapeutic potential in the clinical setting is still extremely limited, mainly because our knowledge of cancer cells MHCI immunopeptidome is rudimentary. Therefore, in order to develop effective therapies, we must understand the mechanism controlling the MHCI immunopeptidome. Without such understanding, a customized and time consuming identification and/or preparation of cancer specific peptides would be required de novo for each patient. Since the immunopeptidome is dependent on both protein translation and degradation, we intend to analyze how major signaling pathways known to play pivotal roles in cancer cells would affect the immunopeptidome. Such understanding will lead us to select particularly attractive peptide targets to prime T-cells ex-vivo for cancer immunotherapy. We will test the efficacy of these peptides to i) prevent the occurrence of spontaneous tumors, and to ii) treat established tumors.
Programme
CIHR Fellowship
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
179040
Name
Rafei Moutih
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
The impact of mTOR and p53 signaling pathways on the MHCI immunopeptidome of cancer cells
Programtype2
Fellowship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Cancer Cells; Chromatography; Immunopeptidome; Mass-Spec; Mhci; Mtor; P53; T-Cell Therapy
Abstract
Cancer cells can be killed effectively by T lymphocytes. In accordance with this concept, studies in mice and humans have clearly shown that T lymphocytes can cure cancer. In order to do so however, T lymphocytes must recognize abnormalities on the surface of cancer cells that are not usually present on normal cells. In essence, T lymphocytes recognize a specific group of small molecules (peptides) that are bound to cell surface proteins called MHCI. Collectively, these peptides are referred to as the MHCI immunopeptidome. We know so far that translation of T-cell therapeutic potential in the clinical setting is still extremely limited, mainly because our knowledge of cancer cells MHCI immunopeptidome is rudimentary. Therefore, in order to develop effective therapies, we must understand the mechanism controlling the MHCI immunopeptidome. Without such understanding, a customized and time consuming identification and/or preparation of cancer specific peptides would be required de novo for each patient. Since the immunopeptidome is dependent on both protein translation and degradation, we intend to analyze how major signaling pathways known to play pivotal roles in cancer cells would affect the immunopeptidome. Such understanding will lead us to select particularly attractive peptide targets to prime T-cells ex-vivo for cancer immunotherapy. We will test the efficacy of these peptides to i) prevent the occurrence of spontaneous tumors, and to ii) treat established tumors.
Competitiondate
200902
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Rafei, Moutih
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~